Type 2 diabetes remission after Roux-en-Y gastric bypass: a multicentered experience with long-term follow-up

Background: Roux-en-Y gastric bypass (RYGB) is associated with short- and mid-term type 2 diabetes (T2D) remission. Long-term outcomes and predictive parameters associated with remission following RYGB have not been well elucidated. Objective: Determining the overall long-term T2D remission rates following RYGB and identifying predictive variables associated with remission. Setting: Multicentered study including patients who underwent RYGB at 3 tertiary referral centers for bariatric surgery. Methods: We performed a retrospective cohort study between 2008-2017 to allow a minimum of 5 years of follow-up. We evaluated long-term T2D remission rates and annual T2D clinical and metabolic parameters up to 14 years after surgery. Predictors of remission were assessed using multivariate logistic regression. Patients were divided into 4 groups based on quartiles of total body weight loss percentage (%TBWL) to compare remission rates between groups. Results: A total of 815 patients were included (68.9% female, age 52.1 +/- 11.5 yr; body mass index 45.1 +/- 7.7 kg/m2) with a follow-up of 7.3 +/- 3.8 years. Remission was demonstrated in 51% of patients. Predictors of remission included pre-operative duration of diabetes, baseline HbA1C, insulin use prior to surgery, number of antidiabetic medications and %TBWL (all P , .01). Remission rates were proportionally associated with %TBWL quartile (Q1, 40.9%; Conclusions: Longer duration and higher severity of T2D were negatively associated with remission while higher %TBWL had a positive association. A significant proportion of patients in all quartiles experienced long-term remission after RYGB with a greater likelihood of remission correlated with greater weight loss. (Surg Obes Relat Dis 2023;19:1339- 1345.) (c) 2023 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.